Orion
As of the edition of 20 October 2026, Orion runs 19 drugs, 3 of them marketed; it is on route A at 1 target and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 3 |
| Active | 3 |
| Went quiet | 9 |
| Stopped | 2 |
| Status not established | 2 |
| Total | 19 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Darolutamide | Ends 2038 (patent) | 1 |
| Levosimendan | none listed | 0 |
| Polyethylene glycol 4000 | none listed | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 1 target, route B at 0 targets.
| Target | Route |
|---|---|
| ADRA2C Alpha-2C adrenergic receptor | Route A |
All 1 row on route A or B
In the product1 company-target row on route A or B; 0 are not shown here, and no score is.
See all 1 targets where Orion needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Nervous system: 8 trials led
- Cancer: 7 trials led
- Heart and blood vessels: 5 trials led